Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.
Linmarie SikichAlexander KolevzonBryan H KingChristopher J McDougleKevin B SandersSoo-Jeong KimMarina SpanosTara ChandrasekharM D Pilar TrellesCarol M RockhillMichelle L PalumboAllyson Witters CundiffAlicia MontgomeryPaige SiperMendy MinjarezLisa A NowinskiSarah MarlerLauren C ShuffreyCheryl AldermanJordana WeissmanBrooke ZapponeJennifer E MullettHope CrossonNatalie HongStephen K SiecinskiStephanie N GiamberardinoSheng LuoLilin SheManjushri BhapkarRussell DeanAbby ScheerJacqueline L JohnsonSimon G GregoryJeremy Veenstra-VanderWeelePublished in: The New England journal of medicine (2021)
This placebo-controlled trial of intranasal oxytocin therapy in children and adolescents with autism spectrum disorder showed no significant between-group differences in the least-squares mean change from baseline on measures of social or cognitive functioning over a period of 24 weeks. (Funded by the National Institute of Child Health and Human Development; SOARS-B ClinicalTrials.gov number, NCT01944046.).